Bernhard Rupp, Ph.D., M.S., Dr. habil.
01.01.1956, Vienna, Austria
Citizen of Austria, EU
Permanent Resident, USA
CEO and Founder, q.e.d. life science discoveries
Adjunct Faculty: University of California, Irvine; Texas A&M University Health Science Center; U. of Wyoming, Laramie.
Previous position: Head of Protein Drug Target Crystallography and Drug Discovery Group
University of California - Lawrence Livermore National Laboratory
|
INSTITUTION AND LOCATION |
DEGREE |
YEAR(s) |
FIELD OF STUDY |
|
University of Vienna, Vienna, Austria |
M.S. |
1974-1982 |
Chemistry |
|
University of Vienna, Vienna, Austria, and ETH Zürich |
Ph.D. |
1984 |
Chemistry |
|
Postdoctoral Fellow, Austrian Science Foundation |
|
1985 |
Structural Chemistry |
|
Lady Davis Fellow, Racah Inst. Physics, Jerusalem, Israel |
|
1986-1987 |
Complex Structures |
|
Postdoctoral Fellow, KFA Jülich, Germany |
|
1987-1988 |
Complex Structures |
|
Guest scientist, Neutron Scattering Laboratory, PSI-ETH Zürich |
|
1988-1989 |
Structural Chemistry |
|
Postdoctoral Fellow, LLNL, Chemistry Dept. |
|
1989-1992 |
Synchrotron Studies |
|
Habilitation (venia docendi), University of Vienna, Austria, Molecular Structural Biology |
Dr. habil. |
1998 |
Structural Biology |
1981 - 1985 : Research and Teaching Associate, Austrian Science Foundation
1986 - 1987 : Lady Davis Fellow, Racah Institute of Physics, Jerusalem, Israel
1987 - 1988 : Research Scientist, Nuclear Research Center (KFA) Jülich, Germany
1988 - 1989 : Guest Scientist, Neutron Scattering Laboratory (LNS), ETH Zürich, Switzerland
1989 - 1992 : University of California, Postdoctoral Fellow at LLNL, CMS Synchrotron Group
1993 - 2000 : University of California, Head of X-ray crystallography group, UC-LLNL
1995 : Tenure, University of California, LLNL
1997 - 2002 : Participating Research Team Leader, Advanced Light Source, LBNL
2002 - 2003 : Visiting Professor, sabbatical research and teaching leave, Texas A&M University
2000 – 2005 : Head, Drug Target Crystallography and Structure Based Drug Discovery Group
UC-LLNL
2005 - Founder and CEO, q.e.d. life science discoveries, California
Adjunct Faculty, UC Irvine; Texas A&M University Health Science Center;
U. of Wyoming, Laramie.
2008: Mini-sabbatical, production phase of book Modern Biomolecular Crystallography
U.S. National Academy of Sciences Committee for Crystallography
Elected student participant of 1982 Nobel Laureate Conference, Lindau/Bodensee. Ph.D. and M.S. with distinction, Forchheimer Award 1986 (Israel). Nominated for the Walter Schottky Prize 1988 for structural and crystallographic work. Stipend for demonstrated excellence by the Academic Senate, University Vienna (three years, 1981-1983). Stipend for outstanding academic achievements by the Austrian Ministry for Science and Research (1981, 1982).
Habilitation (venia docendi) to Univ. Doz. of Molecular Structural Biology, University of Vienna, Austria (1988).
Special Session Chair (Frontiers in Crystallization), American Crystallographic Association Annual Meeting 2001, Los Angeles; Program Committee, BIOS 2002; founding member of the NIH TB Structural Genomics Consortium. Sponsor, 2003 UCLA Seaborg Medal Symposium. Workshop organizer, Macromolecular Structure Validation, ACA Annual meeting 2005, Orlando. Advisory board, Protein Crystallography in Drug Discovery, January 2007, San Francisco.
Elected member of the SSRL Users Organization Executive Committee (1998-2000) and UC BioStar and BioTech Review Panel, member of UCLA Chemistry and Biology Department Advisory Council. Wellcome Trust, DOE OBER/EPSCoR, North Carolina Biotech Center grant review panel. US National Institutes of Health NIAID grant review IRG study section member.
Drug Discovery Today, J. American Chemical Society, J. Bact., Biochemistry, Bioinformatics, J. Biological Chemistry, J. Mol. Biology, J. Structural Biology, J. Mol. Modelling and Graphics, Structure, Nature, Nucleic Acids Research, Proteins, Acta Crystallogr., J. Appl. Crystallogr. and Phys. Rev. and Phys. Rev. Letters reviewer. Faculty of 1000 editorial member (structural biology section).
US National Academy of Sciences National Committee for Crystallography (2008-2011), elected member; American Crystallographic Association Standing Committee for Data Standards and Computing (2005-2008), elected member. ACA education summit committee member. Invited speaker at numerous national and international meetings. Listed among top 24 Austrian Research Scientists abroad.
National Academy of Sciences Keck Futures Panel member "The Genomic Revolution: Implications for Treatment and Control of Infectious Disease"
Research in structural proteomics, automation technology, biophysical chemistry, instrumentation development and crystallographic computing, combined with experience in hypothesis driven structure based drug discovery and design. Strong leadership and team building skills, 16+ years personnel and financial management experience of extramurally funded proteomics and drug target crystallography work. Established drug target crystallography and structure based drug discovery group at UC-LLNL, crystal structures of antibody fragments, superantigen vaccines, apolipoptoteins, Mycobacterium tuberculosis drug targets, clostridial neurotoxins. High throughput crystallization and crystallography, automation technology, mechatronics, structural genomics of drug targets structures, crystallographic computing and validation, structure guided drug discovery, virtual ligand screening, machine learning and data mining. Consultant for several US biotech ventures, universities, and instrument manufacturers. Experience in patenting, licensing, and intellectual property protection. Univ. Dozent (Dr. habil.) for Molecular Structural Biology, University of Vienna, Austria. Excellent academic teaching and instruction record, teaching web site for biomolecular crystallography and structural biology with tutorials. Member of the U.S. National Academy of Sciences Committee for Crystallography and NAS Keck Futures Initiatives panel.
Integration of technology-driven high throughput discovery methods, biophysics, crystallography, structural bioinformatics and data mining with hypothesis driven interests into strong biomedical drug discovery research program. Establishment of interdisciplinary proteomics and drug discovery program in highly collaborative environment, expanding exploration of genetics, structure-function relationships and interaction networks to a systems-level employing novel approaches at the interface of genomics, medicine, biology and bioinformatics. Establishment of a venture employing an innovative and unique combination of genetic screening and directed evolution with structure based drug discovery methods, technologies, and systems analysis to the design of antimicrobials, antivirals and oncotherapeutics.